Evidence map›Paper›PMID 41807027›Full record

ArticleJournal of Korean medical science2026

High-Grade Astrocytoma With Piloid Features: An Aggressive Clinicogenomic Entity Distinct From Pilocytic Astrocytoma.

Jeongwan Kang, Eric Eunshik Kim, Kwanghoon Lee, Seong-Ik Kim, Jin Woo Park, Jae Kyung Won, Ji Hoon Phi, Seung-Ki Kim, Chul-Kee Park, Hyunju Lee and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jeongwan Kang *Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2111-2912
Eric Eunshik Kim *Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5020-9150
Kwanghoon LeeDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9000-5902
Seong-Ik KimDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7713-3782
Jin Woo ParkDepartment of Pathology, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-0801-8208
Jae Kyung WonDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-1459-8093
Ji Hoon PhiDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9603-5843
Seung-Ki KimDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0039-0083
Chul-Kee ParkDepartment of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2350-9876
Hyunju LeeArtificial Intelligence Graduate School, Gwangju Institute of Science and Technology, Gwangju, Korea.ORCID https://orcid.org/0000-0003-2389-7183
Sung-Hye ParkDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8681-1597

Funding

Institute of Information & Communications Technology Planning & Evaluation 2019-0-00567SNUH Kun-hee Lee Child Cancer & Rare Disease Project 24C-039-0000
6 · The paper itself

Abstract

backgroundHigh-grade astrocytoma with piloid features (HGAP) has recently emerged as an aggressive glioma entity with distinct molecular alterations, yet its clinicogenomic distinction from pilocytic astrocytoma (PA) remains to be fully elucidated. This study aims to clarify the clinical, pathological, and genomic differences between pediatric PA, adult PA, and HGAP, and to provide evidence supporting the recognition of HGAP as a new, aggressive entity.

methodsWe retrospectively analyzed 100 genetically and histopathologically confirmed PA cases (87 pediatric, 13 adult) and 25 HGAP cases (all > 19 years old) diagnosed at Seoul National University Hospital between 2015 and 2024. Next-generation sequencing using a brain tumor-specific gene panel and immunohistochemistry evaluation.

resultsPediatric PAs (median age 7 years) were predominantly cerebellar (61%) and showed classic biphasic histology (72%) with frequent

conclusionHGAP represents a clinically aggressive and molecularly distinct high-grade glioma, clearly separable from pediatric and adult PA. Its poor prognosis and unique genetic drivers justify its recognition as a new entity. Accurate molecular profiling is essential for diagnosis and management of these tumors, and the poor survival outcomes observed in HGAP highlight the need for further larger cohort studies to identify optimal therapeutic strategies.

Indexed as

AstrocytomaBrain NeoplasmsAdolescentAdultAgedChildChild, PreschoolFemaleHigh-Throughput Nucleotide SequencingHumansInfantMaleMiddle AgedMutationNeoplasm GradingOncogene Proteins, FusionBRAF-KIAA1549 fusion protein, humanBRAF protein, humanKRAS protein, humanOncogene Proteins, FusionProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53X-linked Nuclear ProteinAdultAstrocytomaChildGeneticsGlioma

Identifiers

PMID41807027
PMCPMC12976636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.